www.tristatetrek.com
On July 21-23, 2006, cyclists from across the country came together for the third annual Tri-State Trek. Three days and 270 miles later, the pack pedaled into White Plains, New York, to the most spectacular finish in the event's short history. Benefiting research to find a treatment and cure for ALS, this grass-roots event has so far raised more than $190,000, returning an average of 75 percent of participant fundraising each year.
Andrea Consoletti, Silver Star Executive from Uxbridge, Massachusetts, along with her husband, Gregg, Traci Novak, Bronze Star Executive from Charlton, Massachusetts, and Mike Dempsey (husband of Supreme Court Executive Director Pat Dempsey of Raleigh, North Carolina) participated in the 2006 Tri-State Trek. Each member of the team had to raise $1,500 in order to participate.
"I participated in the Tri-State Trek because I wanted to do something to challenge myself,” says Andrea. "I knew it would be hard, especially with not much time to recuperate before heading out each day. However, I thought about those people with ALS — they don't know what part of their body will be affected next.”
The team members also created baskets and raffled other prizes in order to raise the money needed to take part in the Trek.
Andrea recommends everyone do their part to raise awareness about ALS. "If you can't participate in the event, there is always a need for volunteers,” she says. "Actually, without volunteers, the event would not be able to take place!”
The 2006 Tri-State Trek participants applaud as Mat Mendel accepts a $10,000 donation for the event from the HelpAmerica Foundation.
AtHome America was a proud sponsor of the 2006 Tri-State Trek! Our $10,000 donation for the van ad was given in conjunction with more than 300 T-shirts for all those participating in this year's event. As well, we donated another $15,000 to ALS TDF!
Founded in 1999, the ALS Therapy Development Foundation (ALS TDF) is a nonprofit biotechnology company devoted to discovering treatments for patients with ALS. They built an in-house research program that combines the power of a nonprofit mission with the best practices of a for-profit biotechnology company.
ALS TDF built and operates the world's leading ALS testing laboratory and has performed in-depth evaluations of nearly 700 promising drug candidates to date. Over the last six years they have completed 150 in vivo studies — twice the number of studies published in the field over the last 10 years and discovered seven drug candidates, including two in clinical trial at the ALS Center, University of California, San Francisco.
